Overview
- In the 100-patient PFLT-PC trial, 84% had no clinically significant cancer in the treated zone on 3‑month biopsy after ProFocal cooled‑laser focal therapy.
- Participants had MRI-visible, localized intermediate-risk disease and were treated transperineally under general anesthesia as a day procedure.
- Ablation was monitored with real-time temperature control at 60–100 °C and assessed by multiparametric MRI within 72 hours, followed by targeted biopsy at three months.
- Functional outcomes were favorable, with erectile dysfunction reported in 12% and minimal urinary impact reflected by a 4.5% decrease in EPIC-urinary scores and low incontinence rates.
- Results were published in BJU International by a team led by Jonathan Kam, with disclosed ties to Medlogical Innovations, including the founder as an author and two authors becoming stockholders after the trial.